Beta© 2026 Adaptrex, LLC
Beta© 2026 Adaptrex, LLC
Federal grant · project grant (b)
Developing Therapeutic Antibodies for Alzheimer's Disease - Project Summary/abstract Millions of Americans Suffer From Alzheimer’s Disease and There Are Currently No Therapies Available to Prevent or Slow the Progression of the Disease. the Unmet Medical Needs of Individuals With Alzheimer’s Disease Result in Hundreds of Billions of Dollars of Costs in Paid and Unpaid Caregiving in the United States Every Year. Versapeutics Is a Small Business Developing Novel Therapeutics for Alzheimer’s Disease. in This Phase I Sbir Project We Will Perform Preclinical Studies to Determine the Feasibility of Antibody-based Therapeutics That Are Designed to Treat Alzheimer’s Disease Using a Unique Mechanism of Action, by Examining Pharmacokinetics, Efficacy, Toxicity and Toxicokinetic. at the Conclusion of These Studies, We Will Have Met Several Important Milestones That Will Support Further Preclinical Development of Our Novel Therapeutics for Alzheimer’s Disease.
Committed
$498,534
Paid out
$429.0K
86%
Committed, not yet paid
$69.5K
14%
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .
Loading…